Physician profile
Jessica Arielle Steen
NPI 1649688847
$256,144.63
in general payments reported to CMS, 2019-2025
31 companies · $122K in 2025
The $122K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,098 · 2020: $473 · 2021: $1,629 · 2022: $3,743 · 2023: $27K · 2024: $100K · 2025: $122K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $78K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $69K · Consulting Fee: $61K · Travel and Lodging: $29K · Food and Beverage: $12K · Honoraria: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $78,250.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68,675.00 |
| Consulting Fee | $61,060.00 |
| Travel and Lodging | $28,802.30 |
| Food and Beverage | $11,664.27 |
| Honoraria | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $106,847.93 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $58,768.47 | 2022-2025 | Tyrvaya, Phentolamine Mesylate |
| Alcon Vision LLC | $47,686.90 | 2019-2025 | Rhopressa, Rocklatan, Tryptyr |
| Carl Zeiss Meditec, INC. | $11,371.86 | 2021-2025 | Cirrus Hd-Oct, Cirrus 6000 With Angioplex, Cirrus 5000 With Angioplex |
| Abbvie INC. | $9,567.59 | 2022-2025 | Vuity |
| Alcon Research LLC | $8,152.16 | 2024-2025 | Rocklatan, Rhopressa |
| Thea Pharma INC. | $4,391.22 | 2023-2024 | Iyuzeh |
| Astellas Pharma US INC | $1,800.00 | 2024-2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $1,173.71 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $1,054.21 | 2021-2024 | Radius |
| Johnson & Johnson Vision Care, INC. | $819.43 | 2019-2023 | Acuvue |
| Allergan, INC. | $469.18 | 2019-2022 | |
| Dompe US, INC. | $464.34 | 2021-2025 | Oxervate |
| Lkc Technologies, INC. | $450.00 | 2025 | |
| Sun Pharmaceutical Industries INC. | $427.51 | 2020-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $412.74 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $344.88 | 2019-2021 | |
| Topcon Healthcare, INC. | $300.00 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $285.94 | 2019-2021 | |
| Optovue, INC. | $248.72 | 2019-2020 | |
| Carl Zeiss Meditec USA, INC. | $230.00 | 2023 | Humphrey Field Analyzer (Hfa3), Cirrus Hd-Oct, Visumax |
| Visionix USA, INC | $141.41 | 2022 | |
| Harrow Eye, LLC | $130.47 | 2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $124.99 | 2019 | |
| Amgen INC. | $121.25 | 2024 | |
| Horizon Therapeutics Plc | $103.96 | 2021 | |
| Optos, INC. | $98.51 | 2020 | |
| Coopervision INC. | $67.87 | 2019 | |
| Ocular Therapeutix, INC. | $50.00 | 2021 | |
| Baxter Healthcare | $27.62 | 2022 | |
| Spark Therapeutics, INC. | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Steen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.